ArticleTranslational cancer research2026
Periostin promotes papillary thyroid carcinoma progression by modulating mTOR/AKT pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) accounts for the prevalent type of thyroid malignancy with increasing incidence. The underlying mechanism facilitating progression is largely unknown. Periostin (POSTN) has been demonstrated to be involved in many cancers, with no clear role of POSTN in PTC progression. This study aimed to explore the function of POSTN in PTC. Methods: Gene expression data from The Cancer Genome Atlas (TCGA) database were analyzed, and tissue and serum samples were obtained from 30 PTC patients and 30 healthy controls. POSTN expression was evaluated using enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blot. Transwell and wound healing experiments were performed to evaluate the function of POSTN in cell migratory abilities. Results: TCGA data revealed elevated Conclusions: POSTN is overexpressed in PTC and shows potential as a prognostic indicator. POSTN expression is associated with tumor progression by regulating AKT/mTOR signaling, which further leads to apoptosis and autophagy. POSTN may also be considered a valuable target for therapeutic strategies in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.